自身免疫性甲状腺疾病的遗传学和表观遗传学:翻译意义

IF 6.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Hanna J. Lee (Assistant Professor), Mihaela Stefan–Lifshitz (Associate Professor), Cheuk Wun Li (Assistant Professor), Yaron Tomer (Professor)
{"title":"自身免疫性甲状腺疾病的遗传学和表观遗传学:翻译意义","authors":"Hanna J. Lee (Assistant Professor),&nbsp;Mihaela Stefan–Lifshitz (Associate Professor),&nbsp;Cheuk Wun Li (Assistant Professor),&nbsp;Yaron Tomer (Professor)","doi":"10.1016/j.beem.2022.101661","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>Hashimoto's thyroiditis (HT) and Graves' disease (GD) are prevalent autoimmune disorders, representing opposite ends of the clinical spectrum of </span>autoimmune thyroid diseases<span> (AITD). The pathogenesis involves a complex interplay between environment and genes. Specific susceptibility genes have been discovered that predispose to AITD, including thyroid-specific and immune-regulatory genes. Growing evidence has revealed that genetic<span> and epigenetic variants can alter </span></span></span>autoantigen<span> presentation during the development of immune tolerance<span>, can enhance self-peptide binding to MHC (major histocompatibility complex), and can amplify stimulation of T- and B-cells. These gene-driven mechanistic discoveries lay the groundwork for novel treatment targets. This review summarizes recent advances in our understanding of key AITD susceptibility genes (Tg</span></span></span><span><sup>1</sup></span>, <span>TSHR</span>, <u>HLA-DR3</u>, and <span>CD40</span>) and their translational therapeutic potential.</p></div>","PeriodicalId":8810,"journal":{"name":"Best practice & research. Clinical endocrinology & metabolism","volume":"37 2","pages":"Article 101661"},"PeriodicalIF":6.1000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550878/pdf/nihms-1822154.pdf","citationCount":"13","resultStr":"{\"title\":\"Genetics and epigenetics of autoimmune thyroid diseases: Translational implications\",\"authors\":\"Hanna J. Lee (Assistant Professor),&nbsp;Mihaela Stefan–Lifshitz (Associate Professor),&nbsp;Cheuk Wun Li (Assistant Professor),&nbsp;Yaron Tomer (Professor)\",\"doi\":\"10.1016/j.beem.2022.101661\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span><span>Hashimoto's thyroiditis (HT) and Graves' disease (GD) are prevalent autoimmune disorders, representing opposite ends of the clinical spectrum of </span>autoimmune thyroid diseases<span> (AITD). The pathogenesis involves a complex interplay between environment and genes. Specific susceptibility genes have been discovered that predispose to AITD, including thyroid-specific and immune-regulatory genes. Growing evidence has revealed that genetic<span> and epigenetic variants can alter </span></span></span>autoantigen<span> presentation during the development of immune tolerance<span>, can enhance self-peptide binding to MHC (major histocompatibility complex), and can amplify stimulation of T- and B-cells. These gene-driven mechanistic discoveries lay the groundwork for novel treatment targets. This review summarizes recent advances in our understanding of key AITD susceptibility genes (Tg</span></span></span><span><sup>1</sup></span>, <span>TSHR</span>, <u>HLA-DR3</u>, and <span>CD40</span>) and their translational therapeutic potential.</p></div>\",\"PeriodicalId\":8810,\"journal\":{\"name\":\"Best practice & research. Clinical endocrinology & metabolism\",\"volume\":\"37 2\",\"pages\":\"Article 101661\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550878/pdf/nihms-1822154.pdf\",\"citationCount\":\"13\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Best practice & research. Clinical endocrinology & metabolism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1521690X22000483\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Best practice & research. Clinical endocrinology & metabolism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1521690X22000483","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 13

摘要

桥本甲状腺炎(HT)和格雷夫斯病(GD)是流行的自身免疫性疾病,代表了自身免疫性甲状腺疾病(AITD)临床谱的两端。发病机制涉及环境和基因之间复杂的相互作用。已经发现了易患AITD的特异性易感性基因,包括甲状腺特异性和免疫调节基因。越来越多的证据表明,遗传和表观遗传变异可以在免疫耐受的发展过程中改变自身抗原的呈递,可以增强自身肽与MHC(主要组织相容性复合体)的结合,并可以放大对T细胞和B细胞的刺激。这些基因驱动的机制发现为新的治疗靶点奠定了基础。这篇综述总结了我们对AITD关键易感基因(Tg1、TSHR、HLA-DR3和CD40)及其翻译治疗潜力的理解的最新进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Genetics and epigenetics of autoimmune thyroid diseases: Translational implications

Hashimoto's thyroiditis (HT) and Graves' disease (GD) are prevalent autoimmune disorders, representing opposite ends of the clinical spectrum of autoimmune thyroid diseases (AITD). The pathogenesis involves a complex interplay between environment and genes. Specific susceptibility genes have been discovered that predispose to AITD, including thyroid-specific and immune-regulatory genes. Growing evidence has revealed that genetic and epigenetic variants can alter autoantigen presentation during the development of immune tolerance, can enhance self-peptide binding to MHC (major histocompatibility complex), and can amplify stimulation of T- and B-cells. These gene-driven mechanistic discoveries lay the groundwork for novel treatment targets. This review summarizes recent advances in our understanding of key AITD susceptibility genes (Tg1, TSHR, HLA-DR3, and CD40) and their translational therapeutic potential.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.90
自引率
0.00%
发文量
77
审稿时长
6-12 weeks
期刊介绍: Best Practice & Research Clinical Endocrinology & Metabolism is a serial publication that integrates the latest original research findings into evidence-based review articles. These articles aim to address key clinical issues related to diagnosis, treatment, and patient management. Each issue adopts a problem-oriented approach, focusing on key questions and clearly outlining what is known while identifying areas for future research. Practical management strategies are described to facilitate application to individual patients. The series targets physicians in practice or training.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信